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ABSTRACT
In this report, we have tried to gain molecular insight into a single nucleotide 
polymorphism (SNP) in the NEIL2 gene previously identified as “cancer risk modifier” 
for BRCA2 mutation carriers.
To that end, we studied the role of this SNP (rs804271) on NEIL2 transcriptional 
regulation, oxidative DNA damage and genome instability in two independent set of 
samples: The first one was a series of eighty-six BRCA1 and BRCA2 mutation carriers and 
eighty non-carrier controls in which we evaluated the effect of the SNP on NEIL2 gene 
expression and oxidative DNA damage accumulation. The second was a set of twenty 
lymphoblastoid cell lines (LCLs), thirteen BRCA1 mutation carriers and seven non-carriers 
control, that were used to analyze the correlation between NEIL2 mRNA and/or protein 
levels, the oxidative and the double stranded break (DSB) DNA damage levels.
Our results suggest that an excessive production of NEIL2 enzyme, associated 
with the SNP, may have a deleterious effect modifying cancer risk susceptibility 
in BRCA2 mutation carriers. We hypothesize that due to the SNP impact on NEIL2 
transcriptional upregulation, a cascade of events may converge in the accumulation 
of oxidative DNA damage and its posterior conversion into DSBs for this specific group 
of patients.
INTRODUCTION
The tumor suppressor genes BRCA1 and BRCA2 
maintain genomic stability through their involvement in 
homologous recombination (HR) double-stranded break 
DNA repair among other processes [1].
Carrying a mutation in the BRCA1 or BRCA2 genes 
increases a woman’s lifetime risk of developing breast and 
ovarian cancer, although there are considerable differences 
in disease manifestation. At the age of 80, cumulative 
cancer risk for BRCA1 and BRCA2 mutation carriers 
ranges from 72% to 69% for breast cancer development, 
and from 44% to 17% for ovarian cancer [2]. This high 
variability may be explained by other genetic modifiers 
and/or environmental factors.
Given the relation of synthetic lethality that exists 
between one of the components of the Base Excision 
Repair (BER) pathway, PARP1 (poly[ADP-ribose] 
polymerase 1), and both BRCA1 and BRCA2 genes 
[3], it is likely that other members of the BER pathway 
exhibit a similar behavior. We hypothesized that common 
genetic variants in genes involved in BER might modify 
a woman’s lifetime risk of developing breast and ovarian 
cancer if she is a BRCA1 or BRCA2 mutation carrier. In 
particular, two Single Nucleotide Polymorphisms (SNPs) 
in the OGG1 and NEIL2 genes were identified as cancer 
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risk modifiers for BRCA1 and BRCA2 mutation carriers, 
respectively [4]. Although the molecular mechanism 
underlying these associations is not clear yet, both SNPS 
were in transcriptional regulatory regions of genes 
encoding DNA glycosylase enzymes which play an 
important role in the first steps of the pathway. 
The BER pathway corrects base lesions from 
deamination, oxidation or methylation [5, 6] which 
represent the majority of endogenous DNA damage due 
to chemical reactions during cellular metabolism [7]. 
There are 11 DNA glycosylases which have the ability 
of recognizing a wide variety of lesions thanks to a DNA 
binding domain, the helix-hairpin helix DNA binding 
motif (like OGG1) [8] and the helix-2turn-helix domain 
(like NEIL2) [9]. In bi-functional DNA glycosylases, like 
OGG1 or NEIL2, base lesions are excised from the DNA 
thanks to its glycosylase activity and AP lyase activity, 
although they may have different DNA-structure/substrate 
affinities. For example, the OGG1 incises DNA at 8-oxoG 
residues, and is active only on duplex DNAs [10]. In 
contrast, NEIL2 shows preferential activity on bubble 
DNA or single-stranded DNA regions [11] and present 
high incising activity for several cytosine-derived lesions 
with robust activity for 5-hydroxyuracil and weaker 
activity for dihydrouracil, 5-hydroxycytosine, thymine 
glycol and 8-oxoG [10] .
If they are not repaired, these lesions may evolve 
into mutation (C:G→T transversions [12] or DNA single-
strand [7] or double-strand breaks (DSBs) [13, 14], which 
are the principal source of genomic instability [15, 16]. 
Certain SNPs in DNA glycosylase genes could 
affect negatively to the general performance of the 
BER pathway and contribute by increasing the levels 
of genome instability and hence to a higher cancer risk, 
especially in presence of a defective BRCA1 or BRCA2 
background. As an example, we previously identified that 
the single nucleotide polimorphism “rs2304277”, located 
1.8Kb downstream the 3’-untranslated region (UTR) of 
OGG1 gene,  was associated with an increased ovarian 
cancer risk for BRCA1 mutation carriers [4]. We tried to 
explain this cancer association at a molecular level and we 
discovered that the SNP was associated with a constitutive 
OGG1 transcriptional down-regulation, which contributed 
to a higher genome and telomere instability, especially in 
those individuals harboring mutations in BRCA1 [17]. 
Similarly, the SNP rs804271, localized within the 
NEIL2 promoter region, is associated with increased 
breast cancer risk for BRCA2 mutation carriers [4]. This 
SNP forms part of several transcription-factor binding 
motifs that are responsive to oxidative stress [18]. It has 
previously been reported that SNPs 5´- UTR  upstream 
the coding region of the NEIL2 gene influence gene 
transcription levels and alter levels of genetic damage 
[19]. In this study, we have explored in two independent 
set of samples with different BRCA status the role of this 
SNP at transcriptional level and its possible implication on 
DNA damage and genome instability to explain its cancer 
risk modifier effect.
RESULTS 
SNP frequency in FBOC series 
We genotyped the rs804271 in FBOC (familial 
breast and ovarian cancer) individuals, and we found 
a SNP allelic frequency of 0.39, similar as reported for 
European population 0.41 in Ensembl data base (http://
www.ensembl.org). No significant differences in the 
genotypic frequencies were detected among the different 
BRCA and control groups (Supplementary Table 1). 
NEIL2 mRNA levels are activated by rs804271 
SNP: In silico studies (HaploReg and GTEX 
public data), FBOC series and LCLs
The SNP rs804271 is located at the 5′- UTR region 
of the NEIL2 gene, within a transcriptional regulatory 
domain at Transcriptional Start Site (TSS) of the gene. We 
explored the possible phenotypic effects of this SNP by 
using HaploReg Database web server [20] and we found 
that 18 proteins are predicted to interact within TSS and 3 
binding motifs for transcription factors TFs (E2F1, SIN3A 
and YY1) are predicted to be altered in the presence of this 
specific SNP (rs804271), (Supplementary Table 2). 
Because transcriptional changes could be expected 
due to the modifications by this SNP at the TSS, we used 
the GTEx eQTL web server [21] (http://www.gtexportal.
org) to test whether rs804271 was associated with changes 
on NEIL2 mRNA levels in different tissues. Overall, we 
found significant increased NEIL2 mRNA levels for 30 
tissues, including breast (p = 1*10−4), ovary (p = 1.4 
* 10−14), and blood (p = 6.6 * 10−13), Supplementary 
Table 3 although in some of them, such as “Cells - 
EBV-transformed lymphocytes (LCLs)” the effect was 
“moderated” (Supplementary Figure 1).
In parallel, we measured NEIL2 mRNA expression 
levels in FBOC series considering both, the BRCA 
mutational status and the presence or absence of the 
NEIL2- variant to stratify and compare expression values 
among groups. We found no significant differences in 
the NEIL2 mRNA levels between BRCA1 and/or BRCA2 
mutation carriers compared to controls (Figure 1A). In 
contrast, when we stratified by the presence of the SNP 
we detected a common NEIL2 mRNA up-regulation 
pattern that was similar for each BRCA mutational group 
(Figure 1B). We performed linear regression analysis to 
confirm that the rs804271 was associated with significant 
higher NEIL2 mRNA levels (β = 0.24; p = 0.01) among 
the FBOC individuals. 
Finally, we measured NEIL2 mRNA basal levels 
among the 20 LCLs considering the BRCA and SNP 
status. Although we detected higher NEIL2 mRNA levels 
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for those LCLs harboring the SNP, these differences were 
not significant (Supplementary Figure 2). This result 
confirmed the tissue variability previously observed in the 
data provided by GTEX (Supplementary Figure 1). 
NEIL2 mRNA and protein levels are correlated 
and both predict NEIL2-derived DNA damage
Because protein sample from FBOC series was 
not available, we decided to use the LCL panel (n = 20) 
to test NEIL2 protein levels (Supplementary Figure 3). 
Spearman correlation analysis confirmed that NEIL2 
mRNA and protein levels were significantly correlated 
among LCLs in basal conditions (r = 0.51; p = 0.02), 
Figure 2A.
In parallel, we measured in the DNA extracted 
from the same LCLs (n = 20), the amount of base 
lesions that are recognized and processed by NEIL2 
(NEIL2-lesions) at telomeres (detailed information 
in the material and methods section). We selected this 
region because  NEIL-protein family members have 
been described to be active at telomeres [22]. Then, we 
performed a correlation analysis between the NEIL2 
mRNA/ protein levels and the relative number of 
“NEIL2-lesions” detected, independently of the BRCA 
or the SNP status. We found that both NEIL2 mRNA and 
NEIL2 protein levels were significantly correlated with 
the relative number of telomeric “NEIL2-lesions¨ (r = 
0.65; p = 0.001 and r = 0.51; p = 0.01, respectively), 
(Figure 2B and 2C). 
The rs804271 is associated to higher levels of 
NEIL2-lesions at telomeres in FBOC series
When considering the BRCA status and NEIL2 
genotypes, we found significantly higher amount of 
“NEIL2-lesions” in BRCA1 and BRCA2 mutation 
carriers compared with controls (p = 0.01 and p < 0.0001 
respectively), (Figure 3A). Moreover, when we considered 
the presence of the SNP (rs804271) we found that those 
individuals presenting both genetic events (BRCA 
mutation together with the SNP) presented significantly 
higher levels of “NEIL2-lesions”, compared to their 
BRCA1/ BRCA2 counterparts without the SNP or controls 
(p < 0.05), (Figure 3B).
Because FPG (formamidopyrimidine [fapy]-DNA 
glycosylase) (e. coli) recognizes specifically oxidative 
purines lesions (8-oxoG/methylFapyG) [23], we measured 
in the DNA from our FBOC individuals the relative 
amount of “FPG-lesions”. Then, we performed correlation 
analysis between (“FPG-lesions” and “NEIL2-lesions”) 
and we detected a significant correlation between both 
type of lesions (r = 0.40; p = 0,03), (Supplementary 
Figure 4A), which suggest that that from the wide range 
of lesions that NEIL2 can recognize [10], the presence 
of the SNP among BRCA1 and BRCA2 mutation carriers 
lead preferentially to the accumulation of purine lesions 
(8-oxoG or methylFapyG).
Because telomeres are susceptible to uracil miss 
incorporation which is primarily recognized and removed 
by the uracil DNA glycosylase (UNG) [24], we have 
Figure 1: (A) Comparative analysis of NEIL2 mRNA expression according BRCA mutational status in FBOC series (BRCA1 and BRCA2 
mutation carriers are compared with Controls). (B) Comparative analysis of NEIL2 mRNA expression according the SNP status ((Carriers 
(GT/TT) Vs Non-carriers (GG)) among the different FBOC groups (BRCA1, BRCA2 mutation carriers and BRCA1/BRCA2 non-carrier 
Controls). Bars represent the mean and the standard deviation for each group. Unpaired student t test was used to test for potential significant 
differences between means. (*p < 0.05). 
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Figure 2: (A) Correlation analysis between NEIL2 mRNA and protein levels. (B) Correlation analysis between NEIL2 mRNA levels and 
the relative amount of “NEIL2-lesions”. (C) Correlation analysis between the NEIL2 protein levels and the relative amount of “NEIL2-
lesions”. Spearman test, was used to test whether correlation is significant. significant p-value when (p < 0.05).
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measured the relative amount of uracil miss incorporation 
at the telomere region as NEIL2 is not able to recognize/
process this type of lesions. We performed correlation 
analysis between “Uracil-lesions” and “NEIL2-lesions” 
and we found no significant correlation between them 
(Supplementary Figure 4B) 
NEIL2-derived DNA damage correlates with 
γH2AX intensity signal
We measured the γH2AX signal intensity in the 
cell nucleus of the 20 LCLs (as a marker of DSBs) at 
basal conditions. We found a direct correlation between 
the relative amount of “NEIL2-lesions¨ and the nuclear 
γH2AX intensity signal independently of the BRCA or 
SNP status (r = 0.31; p = 0.09), (Figure 4).
DISCUSSION
In the present study, we have tried to gain molecular 
insights into a common genetic variant (rs804271) 
previously reported by our group to be associated with 
increased breast cancer risk in BRCA2 mutation carriers 
[4]. For that, we have used two independent set of samples 
to test the SNP effect on NEIL2 transcriptional regulation 
and its possible implication on genome instability.
This SNP is localized within the TSS of NEIL2 gene. 
Previous characterization of the NEIL2 promoter region 
showed that NEIL2 transcription is influenced by certain 
SNPs located 5′ upstream of the start site [19]. Indeed, in 
silico analysis predicted that this polymorphism is located 
within a binding motif for several transcription factors 
(Supplementary Table 2), and transcriptional modifications 
due to this SNP may be expected. 
Data from Gtex confirmed that the presence of 
rs804271 was associated with a significant mRNA 
upregulation in 30 tissues including breast (p = 0.00001), 
ovary (p = 1.4 * 10−14), and blood (p = 6.6 * 10−13), 
(Supplementary Table 3). However, for some tissues, 
such as “Cells - EBV-transformed lymphocytes (LCLs)”, 
this effect was “moderate” (Supplementary Figure 1), 
suggesting that the intensity of the SNP effect may be tissue 
specific. We validated these results in our FBOC series and 
we found, independently of the BRCA status, significantly 
increased NEIL2 mRNA levels in the blood from FBOC 
individuals harboring the SNP (β = 0.24; p = 0.01), 
suggesting that it is associated per se with transcriptional 
activation of the NEIL2 gene. In contrast, we were not able 
to detect a significant NEIL2 mRNA upregulation associated 
to the SNP in the 20 LCL analyzed, confirming the tissue 
specificity found in the GTEX data. All these results 
suggest that rs804271 is indeed associated with constitutive 
transcriptional activation of the NEIL2 gene.
A recent work in which NEIL1 and NEIL2 
(Neil1 −/− /Neil2 −/−) double and NEIL1, NEIL2 and 
NEIL3 (Neil1 −/− /Neil2 −/− /Neil3 −/−) triple knock-out 
mouse models have been characterized, no accumulation 
of oxidative DNA damage, no changes in the mutation 
frequencies under normal physiological conditions and 
more importantly, no cancer predisposition for these mice 
has been observed [25]. This would agree with our results 
in which it is NEIL2 “excess” and not its “absence” that 
Figure 3: (A) Comparative analysis of the relative number of NEIL2-lesions found at telomeres according BRCA mutational status 
in FBOC series (BRCA1 and BRCA2 mutation carriers are compared with Controls). (B) Comparative analysis of the relative amount 
of “NEIL2-lesions” found at telomeres according the SNP status ((Carriers (GT/TT) Vs Non-carriers (GG)) among the different BRCA 
mutational groups in FBOC series (BRCA1, BRCA2 mutation carriers and BRCA1/BRCA2 non-carrier Controls). Unpaired student t test was 
used to test for potential significant differences. (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
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may be deleterious and responsible for the increased risk 
effect of this SNP in BRCA2 mutation carriers.
In the line of this hypothesis, it has been previously 
described that NEIL2 gene is frequently amplified in 
esophageal adenocarcinoma and that tumors with copy 
number gains of NEIL2 gene present significant poor 
prognosis [26, 27]. In addition, we have observed that 
NEIL2 gene is frequently upregulated in several tumor 
types (Supplementary Figure 5A), and more importantly 
that NEIL2 mRNA upregulation or copy number 
amplification has prognostic value for some of those 
tumors (Supplementary Figure 5B).  
The molecular mechanism by which NEIL2 mRNA 
upregulation could be deleterious for BRCA2 mutation 
carriers is unclear. However, high expression levels of BER 
related enzymes have been associated with tissue oxidative 
DNA base damage [12]. In addition, it was described that 
rs804271 (previously ss74800505) was associated with 
both NEIL2 transcriptional modifications and significantly 
increased mutagen-induced genetic damage [19]. In 
fact, in LCLs we found a significant positive correlation 
between the amount of NEIL2 mRNA or protein levels and 
“NEIL2-lesions” (r = 0.65; p = 0.001 and r = 0.51; p = 
0.02, respectively) (Figure 2B). Moreover, in FBOC the 
SNP was also associated with higher amount of “NEIL2-
lesions” compared to their counterparts without the SNP, 
although it was only significant for BRCA1 and BRCA2 
mutation carriers (p = 0.03) (Figure 3B).
A possible explanation for this result, could be 
that the NEIL2 enzyme “excess” as consequence of the 
SNP could lead to the recognition and binding to DNA 
lesions for which normally it presents low excision 
activity, like 8-oxoG [10]. Indeed, we found a significant 
correlation between “NEIL2-lesions” and “FPG-lesions” 
(r = 0.40; p = 0.003) (Supplementary Figure 4A), which 
mostly correspond to purine bases lesions (8-oxoG/
methylFapyG). This could lead to a delay in the repair and 
to the accumulation of “NEIL2-lesions” in the DNA. 
In the context of BRCA1 and BRCA2 deficiency, this 
accumulation of base lesions would be deleterious since 
both enzymes are involved in transcription-coupled repair 
of 8-OxoG [28] and protect against oxidative DNA damage 
converted into DSBs [14]. Indeed, our results in the LCLs 
confirmed that the relative number of “NEIL2-lesions” at 
the telomere was correlated with nuclear γH2AX intensity 
signal (a marker for DSBs) independently of the BRCA or 
SNP status (r = 0.31; p = 0.09) (Figure 4). 
In summary, our hypothesis would be that this SNP 
activates at transcriptional level NEIL2 gene expression 
leading to a cascade of events that converge in the 
accumulation of unresolved “NEIL2-lesions” that may 
be converted into DSBs. In a system with a defective HR 
DNA repair, as it is the case for BRCA2 mutation carriers, 
this SNP would contribute to higher genome instability 
and finally to a higher cancer risk for this specific group 
of patients.
Figure 4: Correlation analysis between relative amount of “NEIL2-lesions” and the γH2AX nuclear intensity signal 
(DSBs). Spearman test, was used to test whether correlation is significant. significant p-value when (p < 0.05).
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MATERIALS AND METHODS
Familial breast and ovarian cancer (FBOC) 
series
We studied a group composed of 166 individuals 
belonging to 51 families meeting high-risk criteria, and 
screened for deleterious mutations in the BRCA1 and 
BRCA2 genes, as reported previously [29]. Of these 
families, 25 carried a deleterious mutation in the BRCA1 
gene, 25 in BRCA2. 
Eighty individuals were used as non-carrier controls: 
they were relatives of BRCA1/2 mutation carriers who did 
not have personal cancer antecedents and did not harbor 
the corresponding familial mutation in the BRCA1 or 
BRCA2 genes. 
All cases and controls signed an appropriate 
informed consent form and the ethics committee of the 
hospital involved (Fuenlabrada University Hospital) 
approved the proposal. 
We used this set of samples to calculate the SNP 
frequency, to quantify NEIL2 mRNA levels in peripheral 
blood and to measure the accumulation of oxidative DNA 
damage at telomeres (NEIL2-lesions, FPG-lesions, uracil 
accumulation) in blood DNA. (Table 1).
Lymphoblastoid cell lines
A second set of 20 LCLs was established by Epstein-
Barr virus transformation of peripheral blood lymphocytes 
from thirteen healthy women carrying heterozygous 
mutations in BRCA1 and seven non-carrier relatives used 
as controls. Mutational analysis had been performed 
by Sanger sequencing (BRCA status) or Taqman probe 
(rs804271) (Supplementary Table 4). None of the women 
included in the study had personal antecedents of cancer. 
This LCL panel has been previously described by our 
group [30]. Cell lines were cultured in RPMI-1640 media 
(Sigma-Aldrich) supplemented with non-heat-inactivated 
20% fetal bovine serum (Sigma-Aldrich), penicillin-
streptomycin (Gibco) and Fungizone (Gibco). The cultures 
were carried out in 25 cm2 flasks (Corning) at 37°C in 
5% CO2 atmosphere and cell lines were maintained in 
exponential growth by daily dilution to 106 cells/ml of 
full media.
We used this sample set to analyze the correlation 
between NEIL2 mRNA – protein levels, the relative 
number of “NEIL2-lesions” found at DNA, and the 
relative number of double stranded brakes (DSB) at DNA.
SNP genotyping (rs804271)
Single Nucleotide Polymorphism  rs1466785, 
located in the NEIL2 gene is a cancer risk modifier for 
BRCA2 mutation carriers [4]. Imputation using 1000 
Genomes data showed that there were several SNPs in 
strong linkage disequilibrium (LD) with rs1466785, the 
original SNP reported in Osorio et al. [4]. Of these, we 
considered rs804271 to be the best candidate, given that 
it showed the most significant associations and that there 
existed functional data supporting its putative role in 
cancer [19]. 
DNA was extracted from peripheral blood of 
FBOC patients or LCLs using MagNAPure LC 2.0 
(Roche Diagnostics, Indianapolis, Indiana) following 
the manufacturer’s instructions. DNA quantification and 
quality were assessed by NanoDrop® (ND-1000 V3.7.1). A 
specific Taqman probe for rs804271 was used to genotype 
the presence/absence of the polymorphism among the 
sample collection. Allelic discrimination assays were 
conducted using the 7900HT Fast Real-Time PCR System 
(Applied Biosystems). Probe design for rs804271 is (G>T) 
instead of (C>A). Along the manuscript we refer to the 
variant as G>T.
NEIL2 mRNA expression analysis 
RNA was extracted from peripheral blood cells 
using TRIzol Reagent (Ambion®, Life Techonogies) 
according to the manufacturer’s instructions. NanoDrop® 
(ND-1000 V3.7.1) was used to assess both RNA 
quantity and quality. Two microliters of cDNA at a final 
concentration of 10-20 ng/μl were mixed in triplicate 
with GoTaq® qPCR MasterMix 1x (Promega), NEIL2 
cDNA primers (F/R) and GAPDH cDNA primers (F/R) 
at final concentrations of 500nM. Primers used were: 
NEIL2 4-5 exons (F: GTCACACCCACCTGTGACAT; 
R: GCACTCAGGACTGAACCGAG) and 
GAPDH (F: CCTGCACCACCAACTGCTTA; R: 
CCATCACGCCACAGTTTCC).All reagents were used 
following the manufacturer’s instructions. qPCR was done 
using the QuantStudio S6 system (Applied Biosystems).
NEIL2 protein quantification
 The expression level of endogenous NEIL2 protein 
was analyzed by western blot. Briefly, cell lysates were 
prepared in RIPA buffer (Sigma) and protease inhibitors 
cocktail (Roche). Protein content was determined by 
Lowry analysis (Bio-Rad). Eighty micrograms of proteins 
were analyzed by SDS-PAGE on polyacrylamide gels 
and transferred to Immobilon-FL membranes (Millipore). 
Membranes were blocked in TBS-T (50 mM Tris-HCl, 
150 mM NaCl, pH 7.5 plus 0.1% Tween 20) and 5% 
nonfat milk for 1 hour at RT. Blots were probed with 
following primary antibodies: rabbit anti-NEIL2 (Atlas 
Antibibodies, #HPA064460) at 1/1000 dilution or mouse 
anti-GAPDH (manufactured by the monoclonal antibodies 
core nit from the Spanish National Cancer Research 
Centre) at 1/3000 dilution in TBS-T containing 5% nonfat 
milk. The secondary antibodies were HRP-conjugated 
(Dako) and the immunoblots were developed using the 
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ECL system (GE Healthcare). ImageLab software version 
4.1 (Bio-Rad) was used for image acquisition and images 
were analyzed using ImageJ software for quantification of 
signal intensity/area for both proteins. 
Oxidative DNA damage studies “NEIL2-lesions”
We used a qPCR-based method to evaluate the 
oxidative DNA damage within telomeric DNA [32], 
based on differences in PCR kinetics between DNA 
template digested by formamidopyrimidine-DNA 
glycosylase (FPG) and undigested DNA. Quantitative 
real-time amplification of genomic DNA was performed 
as described by O’Callaghan et al. [31].
Measurement of telomere damage
Oxidative DNA damage within telomeres 
We used a qPCR-based method to evaluate the 
oxidative stress within telomeric DNA. We followed 
the procedure described by O’Callaghan et al. based 
on differences in PCR kinetics between DNA template 
digested by formamidopyrimidine-DNA-glycosylase 
(FPG) and undigested DNA [32]. Briefly, FPG is a 
bacterial DNA glycosylase that recognizes and cuts the 
oxidized bases from DNA, principally 8-oxoG, AP sites 
that are converted in single-strand breaks (SSBs) by its 
AP-lyase activity. These SSBs reduce amplification 
efficiency, thus, the ΔCq after digesting DNA by FPG (Cq 
digested – Cq undigested) is proportional to the oxidative 
damage in the amplified region. The incubation and 
qPCR amplification of genomic DNA was performed as 
described by O’Callaghan et al. [31]. 
Quantification of “NEIL2-lesions” accumulation 
at telomeres 
The telomere oxidation protocol previously 
described can be potentially adapted to quantify the 
accumulation of different base lesions incubating the DNA 
with other glycosylases that are sensitive to other specific 
base lesions. Following this premise, we used NEIL2 
enzyme to measure the “NEIL2-lesions” accumulation 
(5hydroxyuracildihydrouracil, 5-hydroxycytosine, 
thymine glycol and 8-oxoG) at telomeres [9]. We 
optimized the protocol using a low NEIL2 concentration, 
decreasing DNA amount and incubation time. 200 ng 
of genomic DNA was incubated with 5,6 µM NEIL2 
(provided by Dr. Thomas Helleday, Karolinska Institutet, 
Stockholm, Sweden) or without (replaced with H20) in 
a buffer (25 mM TrisHcl pH 8.0, 15 mM NaCl, 2 Mm 
MgCl2 and 0.0025% Tween 20) for 4 hours at 37°C. The 
reaction was stopped by incubation at 95°C for 5 min. 
qPCR analysis was performed on 10 ng of digested or 
undigested genomic DNA following the same reagents 
and conditions that in the original protocol for FPG [31].
Quantification of uracil accumulation at 
telomeres 
Following this premise, we used UNG to measure 
the accumulation of uracil at telomeres that is recognized 
and excised by this enzyme [33]. We optimized the 
protocol using a low UNG concentration, decreasing DNA 
amount and incubation time. 180 ng of genomic DNA was 
incubated with 130 nM UNG (provided by Dr. Thomas 
Helleday, Karolinska Institutet, Stockholm, Sweden) or 
without (replaced with H20) in a buffer (25 mM TrisHcl 
pH 8.0, 15 mM NaCl, 2 Mm MgCl2 and 0.0025% 
Tween 20) for 30 min at 37°C. The reaction was stopped 
by incubation at 95°C for 5 min. qPCR analysis was 
performed on 10 ng of digested or undigested genomic 
DNA following the same reagents and conditions that in 
the original protocol for FPG [31].
DNA damage 
LCLs were cultured 4 hours before fixation with 
4% paraformaldehyde (Electron Microscopy Sciences, 
Hatfield, Philadelphia, USA). Two hours before fixation, 
cells were counted and seeded into a poly-L-lysine-coated 
(Sigma-Aldrich) μCLEAR bottom 96-well plate (Greiner 
Bio-One) at a density of 75,000 cells per 100ul full media 
per well. LCL were then left for 2 hours to attach to the 
surface of the wells, fixed for 15 min at room temperature, 
permeabilized in 0.5% Triton X-100 in PBS for 20 minutes 
at 4°C and stained with primary and secondary antibodies 
and 4′,6-Diamidino-2-phenylindole dihydrochloride 
(DAPI) to visualize nuclei. To detect γ-H2AX we used 

















BRCA1 25 21 19 40 24 25 14 14
BRCA2 25 23 23 46 30 35 18 18
Controls na 0 0 80 29 25 20 20
Information regarding number of healthy BRCA1 and BRCA2 mutation carriers or cancer cases and the sample size for each 
experimental section.
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mouse monoclonal anti-phospho-histone H2AX antibody 
(Millipore; #05-636). Alexa Fluor 488 from molecular 
probes (Invitrogen; #A-11034) was used, and fluorescent 
images were automatically taken for each well of the 96-
well plate using an Opera High-Content Screening System 
(Perkin Elmer). Pictures were taken under non-saturating 
conditions using a 40x magnification lens to calculate the 
γ-H2AX nuclear signal intensity.
Statistical analysis 
Pearson’s chi-squared test was used to calculate 
whether differences in the frequency of the SNP among the 
FBOC groups were significant (Supplementary Table 1).
We performed linear regression analysis to test 
whether cancer antecedents in BRCA1 and BRCA2 
mutation carriers were associated with any of the variables 
we evaluated in this report, but we did not find significant 
differences (Significant p-values < 0.05) between healthy 
BRCA1 and BRCA2 carriers or cancer cases. Hence, 
we did not stratify for cancer status in these groups 
(Supplementary Table 5).
We considered heterozygotes and homozygotes (GT/
TT)  as a single group, to evaluate the effect of the SNP for 
each of the studied variables, as the cancer modifier effect 
of rs804271 is dominant for BRCA2 mutation carriers [4].
Significant differences for the different comparative 
analysis were stablished by unpaired t test analysis 
(SNP effect on NEIL2 mRNA levels or NEIL2 derived 
base damage accumulation, Figure 1 and Figure 3, 
respectively).
Spearman correlation was used to assess for 
significant correlations between NEIL2 mRNA levels, 
protein levels and NEIL2 derived base damage accumulation 
at telomeres (Figure 3). Also, to assess whether NEIL2-
lesions correlates with “FPG-lesions”, “UNG-lesions” 
and γ-H2AX nuclear signal intensity in FBOC and LCLs 
respectively (Supplementary Figure 4A and Figure 4B).
Statistical calculations were done using SPSS 
version 18 (SPSS Inc., Chicago, Illinois) and GraphPad 
Prism 5.03 (San Diego, California); graphs were made 
using GraphPad Prism 5.03.
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